WallStSmart

Energy Transfer LP (ET)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Energy Transfer LP generates 1566% more annual revenue ($92.29B vs $5.54B). RMD leads profitability with a 27.4% profit margin vs 4.7%. ET appears more attractively valued with a PEG of 0.73. RMD earns a higher WallStSmart Score of 73/100 (B).

ET

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 5.5Value: 8.7Quality: 5.0

RMD

Strong Buy

73

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 5.3Quality: 8.3
Piotroski: 6/9Altman Z: 4.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ETUndervalued (+87.7%)

Margin of Safety

+87.7%

Fair Value

$148.16

Current Price

$19.34

$128.82 discount

UndervaluedFair: $148.16Overvalued
RMDOvervalued (-13.1%)

Margin of Safety

-13.1%

Fair Value

$229.58

Current Price

$206.76

$22.82 premium

UndervaluedFair: $229.58Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ET6 strengths · Avg: 8.5/10
Revenue GrowthGrowth
32.1%10/10

Revenue surging 32.1% year-over-year

Market CapQuality
$68.55B9/10

Large-cap with strong market position

PEG RatioValuation
0.738/10

Growing faster than its price suggests

P/E RatioValuation
16.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$3.38B8/10

Generating 3.4B in free cash flow

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.3%10/10

Strong operational efficiency at 35.3%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.3%9/10

Every $100 of equity generates 25 in profit

Profit MarginProfitability
27.4%9/10

Keeps 27 of every $100 in revenue as profit

Areas to Watch

ET2 concerns · Avg: 2.5/10
Profit MarginProfitability
4.7%3/10

4.7% margin — thin

EPS GrowthGrowth
-3.6%2/10

Earnings declined 3.6%

RMD0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : ET

The strongest argument for ET centers on Revenue Growth, Market Cap, PEG Ratio. Revenue growth of 32.1% demonstrates continued momentum. PEG of 0.73 suggests the stock is reasonably priced for its growth.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.4% and operating margin at 35.3%. Revenue growth of 10.8% demonstrates continued momentum.

Bear Case : ET

The primary concerns for ET are Profit Margin, EPS Growth. Thin 4.7% margins leave little buffer for downturns.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Key Dynamics to Monitor

ET profiles as a hypergrowth stock while RMD is a mature play — different risk/reward profiles.

RMD carries more volatility with a beta of 0.84 — expect wider price swings.

ET is growing revenue faster at 32.1% — sustainability is the question.

ET generates stronger free cash flow (3.4B), providing more financial flexibility.

Bottom Line

RMD scores higher overall (73/100 vs 62/100), backed by strong 27.4% margins and 10.8% revenue growth. ET offers better value entry with a 87.7% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Energy Transfer LP

ENERGY · OIL & GAS MIDSTREAM · USA

Energy Transfer LP offers energy related services. The company is headquartered in Dallas, Texas.

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?